nodes	percent_of_prediction	percent_of_DWPC	metapath
Mianserin—CYP2B6—Irinotecan—lung cancer	0.0374	0.0931	CbGbCtD
Mianserin—CYP2D6—Gefitinib—lung cancer	0.0338	0.0843	CbGbCtD
Mianserin—CYP2B6—Cisplatin—lung cancer	0.0305	0.0759	CbGbCtD
Mianserin—CYP2D6—Vinorelbine—lung cancer	0.026	0.0649	CbGbCtD
Mianserin—CYP1A2—Erlotinib—lung cancer	0.0243	0.0605	CbGbCtD
Mianserin—CYP3A4—Topotecan—lung cancer	0.0235	0.0586	CbGbCtD
Mianserin—CYP3A4—Gefitinib—lung cancer	0.0215	0.0536	CbGbCtD
Mianserin—CYP3A4—Teniposide—lung cancer	0.0209	0.052	CbGbCtD
Mianserin—CYP2B6—Doxorubicin—lung cancer	0.0204	0.0509	CbGbCtD
Mianserin—CYP2D6—Erlotinib—lung cancer	0.02	0.0498	CbGbCtD
Mianserin—CYP1A2—Etoposide—lung cancer	0.0176	0.0437	CbGbCtD
Mianserin—CYP3A4—Vinorelbine—lung cancer	0.0166	0.0413	CbGbCtD
Mianserin—CYP2D6—Vinblastine—lung cancer	0.0161	0.04	CbGbCtD
Mianserin—HTR2A—phrenic nerve—lung cancer	0.0134	0.205	CbGeAlD
Mianserin—CYP3A4—Crizotinib—lung cancer	0.0132	0.0328	CbGbCtD
Mianserin—CYP3A4—Erlotinib—lung cancer	0.0127	0.0317	CbGbCtD
Mianserin—CYP3A4—Paclitaxel—lung cancer	0.0116	0.029	CbGbCtD
Mianserin—CYP3A4—Irinotecan—lung cancer	0.0115	0.0286	CbGbCtD
Mianserin—CYP3A4—Vinblastine—lung cancer	0.0102	0.0254	CbGbCtD
Mianserin—CYP2D6—Doxorubicin—lung cancer	0.00986	0.0246	CbGbCtD
Mianserin—CYP3A4—Etoposide—lung cancer	0.0092	0.0229	CbGbCtD
Mianserin—CYP3A4—Docetaxel—lung cancer	0.00841	0.021	CbGbCtD
Mianserin—HTR7—pulmonary artery—lung cancer	0.00782	0.119	CbGeAlD
Mianserin—CYP3A4—Doxorubicin—lung cancer	0.00627	0.0156	CbGbCtD
Mianserin—HTR2A—pulmonary artery—lung cancer	0.00488	0.0744	CbGeAlD
Mianserin—HRH4—bone marrow—lung cancer	0.00361	0.0551	CbGeAlD
Mianserin—HRH2—cardiac atrium—lung cancer	0.0018	0.0274	CbGeAlD
Mianserin—SLC6A3—respiratory system—lung cancer	0.00169	0.0258	CbGeAlD
Mianserin—SLC6A4—respiratory system—lung cancer	0.00155	0.0237	CbGeAlD
Mianserin—HRH2—lung—lung cancer	0.00137	0.021	CbGeAlD
Mianserin—SLC6A2—respiratory system—lung cancer	0.00137	0.0208	CbGeAlD
Mianserin—HTR7—respiratory system—lung cancer	0.00132	0.0201	CbGeAlD
Mianserin—DRD2—respiratory system—lung cancer	0.00124	0.019	CbGeAlD
Mianserin—HTR7—epithelium—lung cancer	0.0011	0.0168	CbGeAlD
Mianserin—CYP1A2—respiratory system—lung cancer	0.00105	0.016	CbGeAlD
Mianserin—CYP2B6—respiratory system—lung cancer	0.00101	0.0153	CbGeAlD
Mianserin—ADRA2C—bronchus—lung cancer	0.000995	0.0152	CbGeAlD
Mianserin—HRH1—respiratory system—lung cancer	0.000982	0.015	CbGeAlD
Mianserin—HTR7—trachea—lung cancer	0.000972	0.0148	CbGeAlD
Mianserin—HRH2—lymph node—lung cancer	0.00094	0.0143	CbGeAlD
Mianserin—SLC6A3—lung—lung cancer	0.000898	0.0137	CbGeAlD
Mianserin—ADRA2C—trachea—lung cancer	0.000894	0.0136	CbGeAlD
Mianserin—ADRA2C—cardiac atrium—lung cancer	0.000839	0.0128	CbGeAlD
Mianserin—CYP2B6—bronchus—lung cancer	0.000828	0.0126	CbGeAlD
Mianserin—SLC6A4—lung—lung cancer	0.000823	0.0126	CbGeAlD
Mianserin—HRH1—epithelium—lung cancer	0.000821	0.0125	CbGeAlD
Mianserin—HTR2A—respiratory system—lung cancer	0.00082	0.0125	CbGeAlD
Mianserin—HTR2B—lung—lung cancer	0.000816	0.0124	CbGeAlD
Mianserin—ADRA2A—bronchus—lung cancer	0.000794	0.0121	CbGeAlD
Mianserin—HRH1—trachea—lung cancer	0.000726	0.0111	CbGeAlD
Mianserin—SLC6A2—lung—lung cancer	0.000725	0.0111	CbGeAlD
Mianserin—ADRA2A—trachea—lung cancer	0.000713	0.0109	CbGeAlD
Mianserin—HTR7—lung—lung cancer	0.000699	0.0107	CbGeAlD
Mianserin—HTR2A—epithelium—lung cancer	0.000686	0.0105	CbGeAlD
Mianserin—ADRA2A—cardiac atrium—lung cancer	0.00067	0.0102	CbGeAlD
Mianserin—DRD2—lung—lung cancer	0.00066	0.0101	CbGeAlD
Mianserin—ADRA2C—lung—lung cancer	0.000642	0.00979	CbGeAlD
Mianserin—HTR2A—trachea—lung cancer	0.000606	0.00925	CbGeAlD
Mianserin—HTR2B—lymph node—lung cancer	0.000558	0.00851	CbGeAlD
Mianserin—CYP1A2—lung—lung cancer	0.000557	0.0085	CbGeAlD
Mianserin—CYP2B6—lung—lung cancer	0.000534	0.00815	CbGeAlD
Mianserin—HRH1—lung—lung cancer	0.000522	0.00796	CbGeAlD
Mianserin—ADRA2A—lung—lung cancer	0.000512	0.00782	CbGeAlD
Mianserin—SLC6A2—lymph node—lung cancer	0.000496	0.00756	CbGeAlD
Mianserin—ADRA2C—lymph node—lung cancer	0.000439	0.0067	CbGeAlD
Mianserin—HTR2A—lung—lung cancer	0.000436	0.00665	CbGeAlD
Mianserin—Thrombocytopenia—Irinotecan—lung cancer	0.000429	0.00142	CcSEcCtD
Mianserin—Oedema—Gemcitabine—lung cancer	0.000427	0.00141	CcSEcCtD
Mianserin—Hepatitis—Docetaxel—lung cancer	0.000426	0.00141	CcSEcCtD
Mianserin—Dizziness—Vinblastine—lung cancer	0.000423	0.0014	CcSEcCtD
Mianserin—Convulsion—Cisplatin—lung cancer	0.000422	0.0014	CcSEcCtD
Mianserin—Connective tissue disorder—Docetaxel—lung cancer	0.000419	0.00138	CcSEcCtD
Mianserin—Nervous system disorder—Gemcitabine—lung cancer	0.000419	0.00138	CcSEcCtD
Mianserin—Thrombocytopenia—Gemcitabine—lung cancer	0.000418	0.00138	CcSEcCtD
Mianserin—Myalgia—Cisplatin—lung cancer	0.000415	0.00137	CcSEcCtD
Mianserin—Skin disorder—Gemcitabine—lung cancer	0.000415	0.00137	CcSEcCtD
Mianserin—Anaemia—Etoposide—lung cancer	0.000413	0.00136	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.000412	0.00136	CcSEcCtD
Mianserin—Dizziness—Topotecan—lung cancer	0.000411	0.00136	CcSEcCtD
Mianserin—Tremor—Paclitaxel—lung cancer	0.00041	0.00136	CcSEcCtD
Mianserin—Hypotension—Irinotecan—lung cancer	0.000409	0.00135	CcSEcCtD
Mianserin—Dizziness—Erlotinib—lung cancer	0.000406	0.00134	CcSEcCtD
Mianserin—Anaemia—Paclitaxel—lung cancer	0.000405	0.00134	CcSEcCtD
Mianserin—Agitation—Paclitaxel—lung cancer	0.000402	0.00133	CcSEcCtD
Mianserin—Breast disorder—Methotrexate—lung cancer	0.000401	0.00133	CcSEcCtD
Mianserin—Vertigo—Etoposide—lung cancer	0.000401	0.00133	CcSEcCtD
Mianserin—Headache—Vinblastine—lung cancer	0.0004	0.00132	CcSEcCtD
Mianserin—Leukopenia—Etoposide—lung cancer	0.0004	0.00132	CcSEcCtD
Mianserin—Hypotension—Gemcitabine—lung cancer	0.000399	0.00132	CcSEcCtD
Mianserin—Eye disorder—Docetaxel—lung cancer	0.000398	0.00132	CcSEcCtD
Mianserin—Oedema—Cisplatin—lung cancer	0.000398	0.00132	CcSEcCtD
Mianserin—Cardiac disorder—Docetaxel—lung cancer	0.000396	0.00131	CcSEcCtD
Mianserin—Cardiac failure—Doxorubicin—lung cancer	0.000394	0.0013	CcSEcCtD
Mianserin—Paraesthesia—Irinotecan—lung cancer	0.000393	0.0013	CcSEcCtD
Mianserin—Vertigo—Paclitaxel—lung cancer	0.000393	0.0013	CcSEcCtD
Mianserin—Syncope—Paclitaxel—lung cancer	0.000393	0.0013	CcSEcCtD
Mianserin—Loss of consciousness—Etoposide—lung cancer	0.000392	0.0013	CcSEcCtD
Mianserin—Lethargy—Doxorubicin—lung cancer	0.000392	0.0013	CcSEcCtD
Mianserin—Leukopenia—Paclitaxel—lung cancer	0.000392	0.0013	CcSEcCtD
Mianserin—Rash—Topotecan—lung cancer	0.000392	0.00129	CcSEcCtD
Mianserin—Dermatitis—Topotecan—lung cancer	0.000391	0.00129	CcSEcCtD
Mianserin—Nervous system disorder—Cisplatin—lung cancer	0.00039	0.00129	CcSEcCtD
Mianserin—Somnolence—Irinotecan—lung cancer	0.00039	0.00129	CcSEcCtD
Mianserin—Thrombocytopenia—Cisplatin—lung cancer	0.00039	0.00129	CcSEcCtD
Mianserin—Headache—Topotecan—lung cancer	0.000389	0.00129	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Gemcitabine—lung cancer	0.000389	0.00129	CcSEcCtD
Mianserin—Tachycardia—Cisplatin—lung cancer	0.000388	0.00128	CcSEcCtD
Mianserin—Rash—Erlotinib—lung cancer	0.000387	0.00128	CcSEcCtD
Mianserin—Dermatitis—Erlotinib—lung cancer	0.000387	0.00128	CcSEcCtD
Mianserin—Convulsion—Etoposide—lung cancer	0.000387	0.00128	CcSEcCtD
Mianserin—Angiopathy—Docetaxel—lung cancer	0.000387	0.00128	CcSEcCtD
Mianserin—Skin disorder—Cisplatin—lung cancer	0.000386	0.00128	CcSEcCtD
Mianserin—Hypertension—Etoposide—lung cancer	0.000386	0.00127	CcSEcCtD
Mianserin—Headache—Erlotinib—lung cancer	0.000385	0.00127	CcSEcCtD
Mianserin—Loss of consciousness—Paclitaxel—lung cancer	0.000385	0.00127	CcSEcCtD
Mianserin—Diplopia—Doxorubicin—lung cancer	0.000385	0.00127	CcSEcCtD
Mianserin—Mediastinal disorder—Docetaxel—lung cancer	0.000384	0.00127	CcSEcCtD
Mianserin—Paraesthesia—Gemcitabine—lung cancer	0.000383	0.00127	CcSEcCtD
Mianserin—Asthenia—Vinorelbine—lung cancer	0.000381	0.00126	CcSEcCtD
Mianserin—Somnolence—Gemcitabine—lung cancer	0.000379	0.00125	CcSEcCtD
Mianserin—Convulsion—Paclitaxel—lung cancer	0.000379	0.00125	CcSEcCtD
Mianserin—Gastrointestinal disorder—Irinotecan—lung cancer	0.000378	0.00125	CcSEcCtD
Mianserin—Hypertension—Paclitaxel—lung cancer	0.000378	0.00125	CcSEcCtD
Mianserin—Fatigue—Irinotecan—lung cancer	0.000378	0.00125	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000378	0.00125	CcSEcCtD
Mianserin—Pruritus—Vinorelbine—lung cancer	0.000376	0.00124	CcSEcCtD
Mianserin—Constipation—Irinotecan—lung cancer	0.000375	0.00124	CcSEcCtD
Mianserin—Mental disorder—Docetaxel—lung cancer	0.000374	0.00123	CcSEcCtD
Mianserin—Myalgia—Paclitaxel—lung cancer	0.000373	0.00123	CcSEcCtD
Mianserin—Arthralgia—Paclitaxel—lung cancer	0.000373	0.00123	CcSEcCtD
Mianserin—Hypotension—Cisplatin—lung cancer	0.000372	0.00123	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.00037	0.00122	CcSEcCtD
Mianserin—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000368	0.00122	CcSEcCtD
Mianserin—Fatigue—Gemcitabine—lung cancer	0.000368	0.00122	CcSEcCtD
Mianserin—Confusional state—Etoposide—lung cancer	0.000367	0.00121	CcSEcCtD
Mianserin—Cardiac arrest—Doxorubicin—lung cancer	0.000366	0.00121	CcSEcCtD
Mianserin—Constipation—Gemcitabine—lung cancer	0.000365	0.00121	CcSEcCtD
Mianserin—Pancytopenia—Methotrexate—lung cancer	0.000365	0.00121	CcSEcCtD
Mianserin—Dry mouth—Paclitaxel—lung cancer	0.000365	0.00121	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000362	0.0012	CcSEcCtD
Mianserin—Feeling abnormal—Irinotecan—lung cancer	0.000361	0.00119	CcSEcCtD
Mianserin—Confusional state—Paclitaxel—lung cancer	0.00036	0.00119	CcSEcCtD
Mianserin—Neutropenia—Methotrexate—lung cancer	0.000359	0.00119	CcSEcCtD
Mianserin—Oedema—Paclitaxel—lung cancer	0.000357	0.00118	CcSEcCtD
Mianserin—Paraesthesia—Cisplatin—lung cancer	0.000357	0.00118	CcSEcCtD
Mianserin—Thrombocytopenia—Etoposide—lung cancer	0.000357	0.00118	CcSEcCtD
Mianserin—HRH1—lymph node—lung cancer	0.000357	0.00544	CbGeAlD
Mianserin—Tachycardia—Etoposide—lung cancer	0.000356	0.00118	CcSEcCtD
Mianserin—Skin disorder—Etoposide—lung cancer	0.000354	0.00117	CcSEcCtD
Mianserin—Erectile dysfunction—Methotrexate—lung cancer	0.000354	0.00117	CcSEcCtD
Mianserin—Feeling abnormal—Gemcitabine—lung cancer	0.000352	0.00116	CcSEcCtD
Mianserin—Shock—Paclitaxel—lung cancer	0.000352	0.00116	CcSEcCtD
Mianserin—Dizziness—Vinorelbine—lung cancer	0.000351	0.00116	CcSEcCtD
Mianserin—Nervous system disorder—Paclitaxel—lung cancer	0.00035	0.00116	CcSEcCtD
Mianserin—ADRA2A—lymph node—lung cancer	0.00035	0.00535	CbGeAlD
Mianserin—Thrombocytopenia—Paclitaxel—lung cancer	0.00035	0.00116	CcSEcCtD
Mianserin—Tachycardia—Paclitaxel—lung cancer	0.000349	0.00115	CcSEcCtD
Mianserin—Breast disorder—Doxorubicin—lung cancer	0.000348	0.00115	CcSEcCtD
Mianserin—Skin disorder—Paclitaxel—lung cancer	0.000347	0.00115	CcSEcCtD
Mianserin—Gastrointestinal disorder—Cisplatin—lung cancer	0.000343	0.00114	CcSEcCtD
Mianserin—Anaemia—Docetaxel—lung cancer	0.000343	0.00113	CcSEcCtD
Mianserin—Drowsiness—Methotrexate—lung cancer	0.000342	0.00113	CcSEcCtD
Mianserin—Hypotension—Etoposide—lung cancer	0.000341	0.00113	CcSEcCtD
Mianserin—Rash—Vinorelbine—lung cancer	0.000335	0.00111	CcSEcCtD
Mianserin—Dermatitis—Vinorelbine—lung cancer	0.000335	0.00111	CcSEcCtD
Mianserin—Hypotension—Paclitaxel—lung cancer	0.000334	0.0011	CcSEcCtD
Mianserin—Headache—Vinorelbine—lung cancer	0.000333	0.0011	CcSEcCtD
Mianserin—Syncope—Docetaxel—lung cancer	0.000333	0.0011	CcSEcCtD
Mianserin—Leukopenia—Docetaxel—lung cancer	0.000332	0.0011	CcSEcCtD
Mianserin—Feeling abnormal—Cisplatin—lung cancer	0.000328	0.00108	CcSEcCtD
Mianserin—Paraesthesia—Etoposide—lung cancer	0.000327	0.00108	CcSEcCtD
Mianserin—Loss of consciousness—Docetaxel—lung cancer	0.000326	0.00108	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000326	0.00108	CcSEcCtD
Mianserin—Somnolence—Etoposide—lung cancer	0.000324	0.00107	CcSEcCtD
Mianserin—Hepatobiliary disease—Methotrexate—lung cancer	0.000324	0.00107	CcSEcCtD
Mianserin—Convulsion—Docetaxel—lung cancer	0.000322	0.00106	CcSEcCtD
Mianserin—Paraesthesia—Paclitaxel—lung cancer	0.000321	0.00106	CcSEcCtD
Mianserin—Hypertension—Docetaxel—lung cancer	0.00032	0.00106	CcSEcCtD
Mianserin—Agranulocytosis—Methotrexate—lung cancer	0.000319	0.00106	CcSEcCtD
Mianserin—Somnolence—Paclitaxel—lung cancer	0.000318	0.00105	CcSEcCtD
Mianserin—Myalgia—Docetaxel—lung cancer	0.000316	0.00104	CcSEcCtD
Mianserin—Arthralgia—Docetaxel—lung cancer	0.000316	0.00104	CcSEcCtD
Mianserin—Pancytopenia—Doxorubicin—lung cancer	0.000316	0.00104	CcSEcCtD
Mianserin—Desipramine—CYP2A6—lung cancer	0.000315	0.13	CrCbGaD
Mianserin—Gastrointestinal disorder—Etoposide—lung cancer	0.000315	0.00104	CcSEcCtD
Mianserin—Asthenia—Irinotecan—lung cancer	0.000314	0.00104	CcSEcCtD
Mianserin—Fatigue—Etoposide—lung cancer	0.000314	0.00104	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000314	0.00104	CcSEcCtD
Mianserin—Constipation—Etoposide—lung cancer	0.000312	0.00103	CcSEcCtD
Mianserin—Neutropenia—Doxorubicin—lung cancer	0.000311	0.00103	CcSEcCtD
Mianserin—Dry mouth—Docetaxel—lung cancer	0.000309	0.00102	CcSEcCtD
Mianserin—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000309	0.00102	CcSEcCtD
Mianserin—Fatigue—Paclitaxel—lung cancer	0.000308	0.00102	CcSEcCtD
Mianserin—Hepatitis—Methotrexate—lung cancer	0.000307	0.00102	CcSEcCtD
Mianserin—Asthenia—Gemcitabine—lung cancer	0.000306	0.00101	CcSEcCtD
Mianserin—Constipation—Paclitaxel—lung cancer	0.000306	0.00101	CcSEcCtD
Mianserin—Confusional state—Docetaxel—lung cancer	0.000305	0.00101	CcSEcCtD
Mianserin—Oedema—Docetaxel—lung cancer	0.000303	0.001	CcSEcCtD
Mianserin—Weight increased—Doxorubicin—lung cancer	0.000303	0.001	CcSEcCtD
Mianserin—Pruritus—Gemcitabine—lung cancer	0.000302	0.000998	CcSEcCtD
Mianserin—Feeling abnormal—Etoposide—lung cancer	0.0003	0.000993	CcSEcCtD
Mianserin—Shock—Docetaxel—lung cancer	0.000298	0.000985	CcSEcCtD
Mianserin—Nervous system disorder—Docetaxel—lung cancer	0.000297	0.000982	CcSEcCtD
Mianserin—Thrombocytopenia—Docetaxel—lung cancer	0.000297	0.00098	CcSEcCtD
Mianserin—Drowsiness—Doxorubicin—lung cancer	0.000296	0.00098	CcSEcCtD
Mianserin—Tachycardia—Docetaxel—lung cancer	0.000296	0.000977	CcSEcCtD
Mianserin—Feeling abnormal—Paclitaxel—lung cancer	0.000294	0.000973	CcSEcCtD
Mianserin—Skin disorder—Docetaxel—lung cancer	0.000294	0.000973	CcSEcCtD
Mianserin—Dizziness—Irinotecan—lung cancer	0.00029	0.000958	CcSEcCtD
Mianserin—Jaundice—Doxorubicin—lung cancer	0.000289	0.000955	CcSEcCtD
Mianserin—Eye disorder—Methotrexate—lung cancer	0.000287	0.000949	CcSEcCtD
Mianserin—Tinnitus—Methotrexate—lung cancer	0.000286	0.000947	CcSEcCtD
Mianserin—Asthenia—Cisplatin—lung cancer	0.000285	0.000944	CcSEcCtD
Mianserin—Cardiac disorder—Methotrexate—lung cancer	0.000285	0.000943	CcSEcCtD
Mianserin—Hypotension—Docetaxel—lung cancer	0.000283	0.000936	CcSEcCtD
Mianserin—Hepatobiliary disease—Doxorubicin—lung cancer	0.00028	0.000927	CcSEcCtD
Mianserin—Angiopathy—Methotrexate—lung cancer	0.000279	0.000922	CcSEcCtD
Mianserin—Mediastinal disorder—Methotrexate—lung cancer	0.000277	0.000915	CcSEcCtD
Mianserin—Agranulocytosis—Doxorubicin—lung cancer	0.000277	0.000914	CcSEcCtD
Mianserin—Rash—Irinotecan—lung cancer	0.000276	0.000913	CcSEcCtD
Mianserin—Dermatitis—Irinotecan—lung cancer	0.000276	0.000912	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000276	0.000912	CcSEcCtD
Mianserin—Epinastine—ABCB1—lung cancer	0.000276	0.113	CrCbGaD
Mianserin—Headache—Irinotecan—lung cancer	0.000274	0.000907	CcSEcCtD
Mianserin—Paraesthesia—Docetaxel—lung cancer	0.000272	0.000899	CcSEcCtD
Mianserin—Nortriptyline—CYP2E1—lung cancer	0.000272	0.112	CrCbGaD
Mianserin—Bradycardia—Doxorubicin—lung cancer	0.000271	0.000895	CcSEcCtD
Mianserin—Somnolence—Docetaxel—lung cancer	0.000269	0.00089	CcSEcCtD
Mianserin—Mental disorder—Methotrexate—lung cancer	0.000269	0.00089	CcSEcCtD
Mianserin—Rash—Gemcitabine—lung cancer	0.000269	0.00089	CcSEcCtD
Mianserin—Dermatitis—Gemcitabine—lung cancer	0.000269	0.000889	CcSEcCtD
Mianserin—Headache—Gemcitabine—lung cancer	0.000267	0.000884	CcSEcCtD
Mianserin—Hepatitis—Doxorubicin—lung cancer	0.000266	0.00088	CcSEcCtD
Mianserin—Oxcarbazepine—ALB—lung cancer	0.000266	0.109	CrCbGaD
Mianserin—Gastrointestinal disorder—Docetaxel—lung cancer	0.000261	0.000864	CcSEcCtD
Mianserin—Asthenia—Etoposide—lung cancer	0.000261	0.000864	CcSEcCtD
Mianserin—Connective tissue disorder—Doxorubicin—lung cancer	0.000261	0.000864	CcSEcCtD
Mianserin—Fatigue—Docetaxel—lung cancer	0.000261	0.000863	CcSEcCtD
Mianserin—Constipation—Docetaxel—lung cancer	0.000259	0.000856	CcSEcCtD
Mianserin—Pruritus—Etoposide—lung cancer	0.000258	0.000852	CcSEcCtD
Mianserin—Asthenia—Paclitaxel—lung cancer	0.000256	0.000848	CcSEcCtD
Mianserin—Pruritus—Paclitaxel—lung cancer	0.000253	0.000836	CcSEcCtD
Mianserin—Rash—Cisplatin—lung cancer	0.000251	0.000829	CcSEcCtD
Mianserin—Dermatitis—Cisplatin—lung cancer	0.000251	0.000828	CcSEcCtD
Mianserin—Feeling abnormal—Docetaxel—lung cancer	0.00025	0.000825	CcSEcCtD
Mianserin—Eye disorder—Doxorubicin—lung cancer	0.000249	0.000822	CcSEcCtD
Mianserin—Tinnitus—Doxorubicin—lung cancer	0.000248	0.00082	CcSEcCtD
Mianserin—Anaemia—Methotrexate—lung cancer	0.000247	0.000817	CcSEcCtD
Mianserin—Cardiac disorder—Doxorubicin—lung cancer	0.000247	0.000816	CcSEcCtD
Mianserin—Angiopathy—Doxorubicin—lung cancer	0.000241	0.000798	CcSEcCtD
Mianserin—Dizziness—Etoposide—lung cancer	0.000241	0.000797	CcSEcCtD
Mianserin—Vertigo—Methotrexate—lung cancer	0.00024	0.000794	CcSEcCtD
Mianserin—Mediastinal disorder—Doxorubicin—lung cancer	0.00024	0.000793	CcSEcCtD
Mianserin—Leukopenia—Methotrexate—lung cancer	0.000239	0.000791	CcSEcCtD
Mianserin—Dizziness—Paclitaxel—lung cancer	0.000236	0.000781	CcSEcCtD
Mianserin—Mental disorder—Doxorubicin—lung cancer	0.000233	0.000771	CcSEcCtD
Mianserin—Convulsion—Methotrexate—lung cancer	0.000232	0.000766	CcSEcCtD
Mianserin—Rash—Etoposide—lung cancer	0.00023	0.00076	CcSEcCtD
Mianserin—Dermatitis—Etoposide—lung cancer	0.00023	0.000759	CcSEcCtD
Mianserin—Headache—Etoposide—lung cancer	0.000228	0.000755	CcSEcCtD
Mianserin—Myalgia—Methotrexate—lung cancer	0.000228	0.000753	CcSEcCtD
Mianserin—Arthralgia—Methotrexate—lung cancer	0.000228	0.000753	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000226	0.000748	CcSEcCtD
Mianserin—Rash—Paclitaxel—lung cancer	0.000225	0.000745	CcSEcCtD
Mianserin—Dermatitis—Paclitaxel—lung cancer	0.000225	0.000744	CcSEcCtD
Mianserin—Headache—Paclitaxel—lung cancer	0.000224	0.00074	CcSEcCtD
Mianserin—Desipramine—CYP2E1—lung cancer	0.000224	0.092	CrCbGaD
Mianserin—Confusional state—Methotrexate—lung cancer	0.00022	0.000728	CcSEcCtD
Mianserin—Asthenia—Docetaxel—lung cancer	0.000217	0.000718	CcSEcCtD
Mianserin—Pruritus—Docetaxel—lung cancer	0.000214	0.000708	CcSEcCtD
Mianserin—Nervous system disorder—Methotrexate—lung cancer	0.000214	0.000708	CcSEcCtD
Mianserin—Anaemia—Doxorubicin—lung cancer	0.000214	0.000708	CcSEcCtD
Mianserin—Thrombocytopenia—Methotrexate—lung cancer	0.000214	0.000707	CcSEcCtD
Mianserin—Agitation—Doxorubicin—lung cancer	0.000213	0.000704	CcSEcCtD
Mianserin—Skin disorder—Methotrexate—lung cancer	0.000212	0.000701	CcSEcCtD
Mianserin—Vertigo—Doxorubicin—lung cancer	0.000208	0.000688	CcSEcCtD
Mianserin—Syncope—Doxorubicin—lung cancer	0.000208	0.000687	CcSEcCtD
Mianserin—Leukopenia—Doxorubicin—lung cancer	0.000207	0.000685	CcSEcCtD
Mianserin—Hypotension—Methotrexate—lung cancer	0.000204	0.000674	CcSEcCtD
Mianserin—Loss of consciousness—Doxorubicin—lung cancer	0.000204	0.000673	CcSEcCtD
Mianserin—Convulsion—Doxorubicin—lung cancer	0.000201	0.000663	CcSEcCtD
Mianserin—Dizziness—Docetaxel—lung cancer	0.0002	0.000662	CcSEcCtD
Mianserin—Hypertension—Doxorubicin—lung cancer	0.0002	0.000661	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000199	0.000657	CcSEcCtD
Mianserin—Arthralgia—Doxorubicin—lung cancer	0.000197	0.000652	CcSEcCtD
Mianserin—Myalgia—Doxorubicin—lung cancer	0.000197	0.000652	CcSEcCtD
Mianserin—Paraesthesia—Methotrexate—lung cancer	0.000196	0.000648	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000196	0.000647	CcSEcCtD
Mianserin—Somnolence—Methotrexate—lung cancer	0.000194	0.000642	CcSEcCtD
Mianserin—Dry mouth—Doxorubicin—lung cancer	0.000193	0.000637	CcSEcCtD
Mianserin—Rash—Docetaxel—lung cancer	0.000191	0.000631	CcSEcCtD
Mianserin—Dermatitis—Docetaxel—lung cancer	0.000191	0.000631	CcSEcCtD
Mianserin—Confusional state—Doxorubicin—lung cancer	0.000191	0.00063	CcSEcCtD
Mianserin—Imipramine—CYP2E1—lung cancer	0.00019	0.078	CrCbGaD
Mianserin—Headache—Docetaxel—lung cancer	0.00019	0.000627	CcSEcCtD
Mianserin—Oedema—Doxorubicin—lung cancer	0.000189	0.000625	CcSEcCtD
Mianserin—Amitriptyline—CYP2E1—lung cancer	0.000189	0.0775	CrCbGaD
Mianserin—Gastrointestinal disorder—Methotrexate—lung cancer	0.000188	0.000623	CcSEcCtD
Mianserin—Fatigue—Methotrexate—lung cancer	0.000188	0.000622	CcSEcCtD
Mianserin—Shock—Doxorubicin—lung cancer	0.000186	0.000615	CcSEcCtD
Mianserin—Nervous system disorder—Doxorubicin—lung cancer	0.000185	0.000613	CcSEcCtD
Mianserin—Thrombocytopenia—Doxorubicin—lung cancer	0.000185	0.000612	CcSEcCtD
Mianserin—Tachycardia—Doxorubicin—lung cancer	0.000184	0.00061	CcSEcCtD
Mianserin—Skin disorder—Doxorubicin—lung cancer	0.000184	0.000607	CcSEcCtD
Mianserin—Feeling abnormal—Methotrexate—lung cancer	0.00018	0.000595	CcSEcCtD
Mianserin—Hypotension—Doxorubicin—lung cancer	0.000177	0.000584	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000172	0.000569	CcSEcCtD
Mianserin—Paraesthesia—Doxorubicin—lung cancer	0.00017	0.000561	CcSEcCtD
Mianserin—Somnolence—Doxorubicin—lung cancer	0.000168	0.000556	CcSEcCtD
Mianserin—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000163	0.000539	CcSEcCtD
Mianserin—Fatigue—Doxorubicin—lung cancer	0.000163	0.000539	CcSEcCtD
Mianserin—Constipation—Doxorubicin—lung cancer	0.000162	0.000534	CcSEcCtD
Mianserin—Asthenia—Methotrexate—lung cancer	0.000157	0.000518	CcSEcCtD
Mianserin—Feeling abnormal—Doxorubicin—lung cancer	0.000156	0.000515	CcSEcCtD
Mianserin—Pruritus—Methotrexate—lung cancer	0.000154	0.000511	CcSEcCtD
Mianserin—Nortriptyline—ALB—lung cancer	0.000149	0.0614	CrCbGaD
Mianserin—Dizziness—Methotrexate—lung cancer	0.000144	0.000477	CcSEcCtD
Mianserin—Rash—Methotrexate—lung cancer	0.000138	0.000455	CcSEcCtD
Mianserin—Dermatitis—Methotrexate—lung cancer	0.000138	0.000455	CcSEcCtD
Mianserin—Headache—Methotrexate—lung cancer	0.000137	0.000452	CcSEcCtD
Mianserin—Asthenia—Doxorubicin—lung cancer	0.000136	0.000448	CcSEcCtD
Mianserin—Trimipramine—ABCB1—lung cancer	0.000134	0.0551	CrCbGaD
Mianserin—Pruritus—Doxorubicin—lung cancer	0.000134	0.000442	CcSEcCtD
Mianserin—Dizziness—Doxorubicin—lung cancer	0.000125	0.000413	CcSEcCtD
Mianserin—Rash—Doxorubicin—lung cancer	0.000119	0.000394	CcSEcCtD
Mianserin—Dermatitis—Doxorubicin—lung cancer	0.000119	0.000394	CcSEcCtD
Mianserin—Headache—Doxorubicin—lung cancer	0.000118	0.000391	CcSEcCtD
Mianserin—Desipramine—ABCB1—lung cancer	0.000117	0.0482	CrCbGaD
Mianserin—Amitriptyline—ALB—lung cancer	0.000104	0.0426	CrCbGaD
Mianserin—Imipramine—ABCB1—lung cancer	9.95e-05	0.0409	CrCbGaD
Mianserin—Amitriptyline—ABCB1—lung cancer	9.89e-05	0.0406	CrCbGaD
Mianserin—ADRA2B—Signaling Pathways—SRC—lung cancer	5.88e-06	2.58e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CXCL8—lung cancer	5.87e-06	2.57e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—STK11—lung cancer	5.86e-06	2.57e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—HRAS—lung cancer	5.84e-06	2.56e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—EP300—lung cancer	5.84e-06	2.56e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—MYC—lung cancer	5.84e-06	2.56e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—PIK3CA—lung cancer	5.83e-06	2.56e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—HRAS—lung cancer	5.83e-06	2.56e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—PIK3CA—lung cancer	5.83e-06	2.55e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—EP300—lung cancer	5.81e-06	2.55e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—KRAS—lung cancer	5.8e-06	2.54e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—PIK3CA—lung cancer	5.79e-06	2.54e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling by GPCR—AKT1—lung cancer	5.78e-06	2.53e-05	CbGpPWpGaD
Mianserin—DRD2—GPCR downstream signaling—AKT1—lung cancer	5.77e-06	2.53e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—PTEN—lung cancer	5.75e-06	2.52e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—PIK3CA—lung cancer	5.75e-06	2.52e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—VEGFA—lung cancer	5.73e-06	2.51e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—TP53—lung cancer	5.73e-06	2.51e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MDM2—lung cancer	5.72e-06	2.51e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CASP3—lung cancer	5.72e-06	2.51e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—IL2—lung cancer	5.71e-06	2.5e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—EGFR—lung cancer	5.71e-06	2.5e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—RAF1—lung cancer	5.7e-06	2.5e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—IL6—lung cancer	5.68e-06	2.49e-05	CbGpPWpGaD
Mianserin—HTR2A—GPCR downstream signaling—AKT1—lung cancer	5.68e-06	2.49e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—SRC—lung cancer	5.68e-06	2.49e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—STAT3—lung cancer	5.67e-06	2.49e-05	CbGpPWpGaD
Mianserin—HRH1—GPCR downstream signaling—AKT1—lung cancer	5.67e-06	2.48e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CG—lung cancer	5.66e-06	2.48e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—NRAS—lung cancer	5.66e-06	2.48e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—EP300—lung cancer	5.65e-06	2.48e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—SRC—lung cancer	5.65e-06	2.48e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—TP53—lung cancer	5.64e-06	2.47e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—ERBB2—lung cancer	5.64e-06	2.47e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—TP53—lung cancer	5.64e-06	2.47e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CASP3—lung cancer	5.63e-06	2.47e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—IL2—lung cancer	5.62e-06	2.46e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CASP3—lung cancer	5.62e-06	2.46e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—IL2—lung cancer	5.61e-06	2.46e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—TP53—lung cancer	5.6e-06	2.45e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—IL6—lung cancer	5.59e-06	2.45e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—IL6—lung cancer	5.58e-06	2.45e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CCND1—lung cancer	5.57e-06	2.44e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	5.57e-06	2.44e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MTOR—lung cancer	5.57e-06	2.44e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—JUN—lung cancer	5.56e-06	2.44e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—VEGFA—lung cancer	5.53e-06	2.42e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—VEGFA—lung cancer	5.5e-06	2.41e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—SRC—lung cancer	5.49e-06	2.41e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—EP300—lung cancer	5.49e-06	2.41e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CCND1—lung cancer	5.48e-06	2.4e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—HRAS—lung cancer	5.48e-06	2.4e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—STAT3—lung cancer	5.47e-06	2.4e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—JUN—lung cancer	5.47e-06	2.4e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CCND1—lung cancer	5.47e-06	2.4e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—NRAS—lung cancer	5.46e-06	2.39e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—JUN—lung cancer	5.46e-06	2.39e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—STAT3—lung cancer	5.45e-06	2.39e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—NRAS—lung cancer	5.43e-06	2.38e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—GSTP1—lung cancer	5.43e-06	2.38e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—MAPK3—lung cancer	5.42e-06	2.37e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MMP9—lung cancer	5.41e-06	2.37e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—HRAS—lung cancer	5.4e-06	2.37e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—PTEN—lung cancer	5.39e-06	2.36e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—KRAS—lung cancer	5.39e-06	2.36e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—HRAS—lung cancer	5.39e-06	2.36e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—POMC—lung cancer	5.39e-06	2.36e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CDKN1A—lung cancer	5.39e-06	2.36e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—PTEN—lung cancer	5.37e-06	2.36e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—HRAS—lung cancer	5.36e-06	2.35e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CXCL8—lung cancer	5.35e-06	2.35e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—VEGFA—lung cancer	5.35e-06	2.34e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—PIK3CA—lung cancer	5.33e-06	2.33e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MMP9—lung cancer	5.32e-06	2.33e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—HRAS—lung cancer	5.32e-06	2.33e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MMP9—lung cancer	5.31e-06	2.33e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CDKN1A—lung cancer	5.3e-06	2.32e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—STAT3—lung cancer	5.3e-06	2.32e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CDKN1A—lung cancer	5.29e-06	2.32e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—PTEN—lung cancer	5.29e-06	2.32e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—NRAS—lung cancer	5.28e-06	2.32e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—CAT—lung cancer	5.28e-06	2.31e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—PTEN—lung cancer	5.28e-06	2.31e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—MYC—lung cancer	5.27e-06	2.31e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—APOA1—lung cancer	5.25e-06	2.3e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—CREBBP—lung cancer	5.25e-06	2.3e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—AKT1—lung cancer	5.24e-06	2.3e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—IL6—lung cancer	5.24e-06	2.3e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MAPK3—lung cancer	5.23e-06	2.29e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MAPK3—lung cancer	5.2e-06	2.28e-05	CbGpPWpGaD
Mianserin—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	5.17e-06	2.27e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—IL6—lung cancer	5.17e-06	2.26e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—IL6—lung cancer	5.16e-06	2.26e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—AKT1—lung cancer	5.16e-06	2.26e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—EGFR—lung cancer	5.15e-06	2.26e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—TP53—lung cancer	5.15e-06	2.26e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—AKT1—lung cancer	5.15e-06	2.26e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—EP300—lung cancer	5.14e-06	2.25e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—ABCB1—lung cancer	5.14e-06	2.25e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—IL6—lung cancer	5.13e-06	2.25e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—EP300—lung cancer	5.13e-06	2.25e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CASP3—lung cancer	5.12e-06	2.24e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—IL2—lung cancer	5.11e-06	2.24e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—IL6—lung cancer	5.09e-06	2.23e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MYC—lung cancer	5.09e-06	2.23e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MAPK3—lung cancer	5.06e-06	2.22e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MYC—lung cancer	5.06e-06	2.22e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—TYMS—lung cancer	5.04e-06	2.21e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—EP300—lung cancer	5.04e-06	2.21e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—EP300—lung cancer	5.03e-06	2.21e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	5.03e-06	2.21e-05	CbGpPWpGaD
Mianserin—ADRA2C—Metabolism—PIK3CA—lung cancer	5e-06	2.19e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—GSTM1—lung cancer	4.99e-06	2.19e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CCND1—lung cancer	4.98e-06	2.18e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—SRC—lung cancer	4.98e-06	2.18e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CD—lung cancer	4.98e-06	2.18e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—EGFR—lung cancer	4.98e-06	2.18e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—JUN—lung cancer	4.97e-06	2.18e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—PIK3CA—lung cancer	4.96e-06	2.17e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—EGFR—lung cancer	4.95e-06	2.17e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—HRAS—lung cancer	4.93e-06	2.16e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MYC—lung cancer	4.92e-06	2.16e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—ALB—lung cancer	4.91e-06	2.15e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—SRC—lung cancer	4.9e-06	2.15e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—SRC—lung cancer	4.89e-06	2.14e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—KRAS—lung cancer	4.87e-06	2.13e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—VEGFA—lung cancer	4.85e-06	2.13e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MMP9—lung cancer	4.84e-06	2.12e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—AKT1—lung cancer	4.84e-06	2.12e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	4.82e-06	2.11e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—EGFR—lung cancer	4.81e-06	2.11e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PTEN—lung cancer	4.81e-06	2.11e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—STAT3—lung cancer	4.81e-06	2.11e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CG—lung cancer	4.8e-06	2.1e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—NRAS—lung cancer	4.8e-06	2.1e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—TP53—lung cancer	4.79e-06	2.1e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—VEGFA—lung cancer	4.78e-06	2.09e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—VEGFA—lung cancer	4.77e-06	2.09e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—AKT1—lung cancer	4.77e-06	2.09e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—AKT1—lung cancer	4.76e-06	2.09e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—AKT1—lung cancer	4.73e-06	2.07e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—STAT3—lung cancer	4.73e-06	2.07e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—CYP1A1—lung cancer	4.73e-06	2.07e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—STAT3—lung cancer	4.72e-06	2.07e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—NRAS—lung cancer	4.72e-06	2.07e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—IL6—lung cancer	4.72e-06	2.07e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—NRAS—lung cancer	4.71e-06	2.06e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—KRAS—lung cancer	4.7e-06	2.06e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—AKT1—lung cancer	4.69e-06	2.06e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—ERCC2—lung cancer	4.69e-06	2.05e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—KRAS—lung cancer	4.68e-06	2.05e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MAPK3—lung cancer	4.59e-06	2.01e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—EP300—lung cancer	4.59e-06	2.01e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—HRAS—lung cancer	4.58e-06	2.01e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—POMC—lung cancer	4.57e-06	2e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—KRAS—lung cancer	4.55e-06	1.99e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MAPK3—lung cancer	4.52e-06	1.98e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MAPK3—lung cancer	4.51e-06	1.98e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—PIK3CA—lung cancer	4.47e-06	1.96e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MYC—lung cancer	4.47e-06	1.96e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—SRC—lung cancer	4.46e-06	1.96e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—CREBBP—lung cancer	4.45e-06	1.95e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MYC—lung cancer	4.4e-06	1.93e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—IL6—lung cancer	4.39e-06	1.92e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MYC—lung cancer	4.39e-06	1.92e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—EGFR—lung cancer	4.37e-06	1.91e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—AKT1—lung cancer	4.35e-06	1.91e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—VEGFA—lung cancer	4.35e-06	1.9e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CB—lung cancer	4.34e-06	1.9e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—TP53—lung cancer	4.33e-06	1.9e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—PIK3CA—lung cancer	4.32e-06	1.89e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—STAT3—lung cancer	4.3e-06	1.89e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PTGS2—lung cancer	4.3e-06	1.88e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—EGFR—lung cancer	4.3e-06	1.88e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—PIK3CA—lung cancer	4.3e-06	1.88e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—NRAS—lung cancer	4.29e-06	1.88e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—EGFR—lung cancer	4.29e-06	1.88e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CD—lung cancer	4.22e-06	1.85e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—PIK3CA—lung cancer	4.18e-06	1.83e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—TP53—lung cancer	4.18e-06	1.83e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—ALB—lung cancer	4.16e-06	1.82e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—TP53—lung cancer	4.16e-06	1.82e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—HRAS—lung cancer	4.14e-06	1.81e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—KRAS—lung cancer	4.13e-06	1.81e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MAPK3—lung cancer	4.11e-06	1.8e-05	CbGpPWpGaD
Mianserin—ADRA2C—Metabolism—AKT1—lung cancer	4.08e-06	1.79e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—KRAS—lung cancer	4.06e-06	1.78e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—PIK3CA—lung cancer	4.06e-06	1.78e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—APOA1—lung cancer	4.06e-06	1.78e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—KRAS—lung cancer	4.05e-06	1.78e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—AKT1—lung cancer	4.05e-06	1.77e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—TP53—lung cancer	4.04e-06	1.77e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MYC—lung cancer	4e-06	1.75e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—HRAS—lung cancer	4e-06	1.75e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—HRAS—lung cancer	3.98e-06	1.74e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—IL6—lung cancer	3.96e-06	1.74e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—EGFR—lung cancer	3.91e-06	1.71e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—HRAS—lung cancer	3.87e-06	1.69e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—IL6—lung cancer	3.82e-06	1.68e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—PIK3CA—lung cancer	3.81e-06	1.67e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—IL6—lung cancer	3.8e-06	1.67e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—PIK3CA—lung cancer	3.79e-06	1.66e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PTEN—lung cancer	3.75e-06	1.64e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—PIK3CA—lung cancer	3.73e-06	1.64e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—PIK3CA—lung cancer	3.72e-06	1.63e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CG—lung cancer	3.7e-06	1.62e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—IL6—lung cancer	3.7e-06	1.62e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—KRAS—lung cancer	3.69e-06	1.62e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CB—lung cancer	3.68e-06	1.61e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—TP53—lung cancer	3.67e-06	1.61e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—AKT1—lung cancer	3.65e-06	1.6e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PTGS2—lung cancer	3.64e-06	1.6e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—TP53—lung cancer	3.61e-06	1.58e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—TP53—lung cancer	3.6e-06	1.58e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—EP300—lung cancer	3.58e-06	1.57e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—AKT1—lung cancer	3.53e-06	1.55e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—POMC—lung cancer	3.52e-06	1.54e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—AKT1—lung cancer	3.51e-06	1.54e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—HRAS—lung cancer	3.51e-06	1.54e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—HRAS—lung cancer	3.45e-06	1.51e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—HRAS—lung cancer	3.44e-06	1.51e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—CREBBP—lung cancer	3.43e-06	1.5e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—AKT1—lung cancer	3.41e-06	1.5e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	3.39e-06	1.49e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—IL6—lung cancer	3.36e-06	1.47e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—AKT1—lung cancer	3.32e-06	1.45e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—IL6—lung cancer	3.3e-06	1.45e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—IL6—lung cancer	3.3e-06	1.44e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—TP53—lung cancer	3.28e-06	1.44e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CD—lung cancer	3.25e-06	1.43e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—ALB—lung cancer	3.21e-06	1.41e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PTEN—lung cancer	3.18e-06	1.39e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—HRAS—lung cancer	3.14e-06	1.38e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—AKT1—lung cancer	3.11e-06	1.36e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—AKT1—lung cancer	3.1e-06	1.36e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—AKT1—lung cancer	3.05e-06	1.34e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—AKT1—lung cancer	3.04e-06	1.33e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—EP300—lung cancer	3.03e-06	1.33e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—IL6—lung cancer	3.01e-06	1.32e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CB—lung cancer	2.84e-06	1.24e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PTGS2—lung cancer	2.81e-06	1.23e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—AKT1—lung cancer	2.77e-06	1.22e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CA—lung cancer	2.65e-06	1.16e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PTEN—lung cancer	2.45e-06	1.07e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—EP300—lung cancer	2.34e-06	1.02e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CA—lung cancer	2.24e-06	9.82e-06	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—AKT1—lung cancer	2.16e-06	9.47e-06	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—AKT1—lung cancer	1.83e-06	8.02e-06	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CA—lung cancer	1.73e-06	7.58e-06	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—AKT1—lung cancer	1.41e-06	6.19e-06	CbGpPWpGaD
